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CHAPTER 6
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Objective. To evaluate the therapeutic efficacy of intravesical pentosanpolysulfate (PPS) in intersti-
tial cystitis (IC) patients.
Patients and Methods. After a preliminary pilot-study 20 IC patients participated in a double-blind
placebo-controlled study with intravesical PPS, applied twice a week, for a period of 3 months. All
patients fullfilled the diagnostic NIH-NIADK criteria for IC.
Results. Nineteen patients were evaluable. In the group of patients treated with PPS, 40% expe-
rienced symptomatic relief versus 20% in the placebo-group. Only urodynamic bladder capacity
showed a statistically significant increase in patients treated with PPS (p=0.047). Following the
blinded, controlled period of three months eleven (55%) patients continued PPS instillations. From
the group of patients (n=8) who continued with PPS after 3-months-placebo six (75%) reported
symptomatic improvement.
Conclusions. We concluded the efficacy of intravesical PPS to be slight superior to oral PPS. In




Interstitial Cystitis (IC) includes a large group of patients with bladder pain, irritative voiding
symptoms (urgency, frequency, nocturia and dysuria) and sterile urine. With little certain about its
pathology and etiology a committee convened by the National Institutes of Health has arbitrarily
proposed a set of characteristics to define the disease1. Despite the exponentional growth in clinical
and basic research, no effective standard treatment is available. Small series have reported favou-
rable results with a large variety of drugs, but placebo-controlled studies are rare.
Surface glycosaminoglycans, the ’mucus’ lining of the bladder, have been identified as the
defence mechanism coating and protecting the transitional cell surface2,3. A current etiologic
hypothesis of IC is a defect in the epithelial barrier of the bladder, which allows normal or abnor-
mal substances in the urine to gain inappropriate access to the deeper layers of the bladder wall,
initiating a circle of irritation and recruitment of immune cells and immune-mediated responses.
Experimentally sodium pentosanpolysulfate (PPS), a heparin analogue, has been shown to reinforce
the glycosaminoglycans and reduce transitional cell injury4. These results and theories formed the
rationale to use PPS for the treatment of interstitial cystitis. Different success rates were reported
with oral PPS4 - 9. In a preliminary pilot study at our centre, pentosanpolysulfate was applied
intravesically (300 mg in 50 ml saline 0.9%, twice in a week) instead of orally. Long-term sympto-
matic and objective remission was observed in four out of the six patients, and tolerance was
excellent10.
Based on these results, a placebo-controlled prospective, double-blind study was designed to
evaluate the therapeutic efficacy of intravesical pentosanpolysulfate compared to placebo in IC
patients.
PATIENTS AND METHODS
This study was conducted in a double-blind manner, and a placebo control group was used as a
comparison. The study was unicentered and approved by the Human Investigation Committee at
our hospital. Patients were informed verbally and in written, and informed consent was obtained
from each of them. The requested number of patients for each protocol was estimated before the
trial on the basis of the results of the preliminary pilot-study; the outcome was 10. The treatment
period in both protocols was 3 months.
Patients were recruited from the northern part of the Netherlands, with an estimated population
of 1.7 x 106; our university hospital serving as a primary and referral hospital. Before institution of
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treatment, clinical evaluation comprised routine laboratory examinations, urine culture, urine
cytology, a cystometrogram awake (20 cc fill rate per minute) and cystoscopy under anesthesia with
coldcup biopsies and capacity measurement (1 minute at 80 cm H2O pressure). Patients were
selected for enrollment in the study on the basis of inclusion and exclusion criteria as established
by the N.H.I. of the U.S.A.1. Patients were assigned at random to receive pentosanpolysulfate or
placebo in accordance with a random code providing two parallel groups for comparison: a PPS-
group and a placebo-group. After receiving treatment for three months the code was broken. All the
patients were offered to continue with PPS instillations. Patients who decided to continue received
intravesical PPS for at least an additional 3 months. Positive responders were offered to continue
arbitrarily up to one year, or to participate in another study evaluating the effect of a change in
frequency and composition of the PPS instillations.
Pentosanpolysulfate was ordered commercially (Bayer a.g., München-Germany) as injection
fluid vials (100 mg/ml). The hospital pharmacy converted them into sterile bladder instillations of
300 mg pentosanpolysulfate in 50 cc Urotainer (0.9% sodium chloride). The solution was colour-
less, without odour and remained stable for a minimum of 6 weeks, stored in a refrigerator. All the
patients applied twice weekly intravesical pentosanpolysulfate. The first instillations took place at
the hospital and treatment was continued at home by self-catheterisation, after instructions, or with
the help of a district nurse. Instillations were collected every 3 weeks at the hospital.
Efficacy evaluation was based on subjective and objective parameters. An overall impression of
the symptom-status was recorded at the end of three months. The subjective improvement was
evaluated using a visual analoque scale scoring 1 to 5 points. Treatment was considered to be
successful if there was a 1-point or greater reduction on the severity scale.
Objective parameters. The 24-hour frequency, the average voiding volume, the maximum
volume voided and the nocturia were recorded from a 48-hour voiding chart completed by the
patient before treatment started and at 6-weekly intervals. A cystometrogram was performed before
installment of therapy and after 3 months, using a flow rate of 20 ml/min. Urodynamic capacity
was defined as the voided volume after maximum filling increased with the residual bladder
volume. In this way, differences in diuresis during the filling phase were eliminated. Normal desire
volume was defined as the feeling that leads the patient to pass urine at the next convenient
moment.
Data analysis. Parameters were analysed between the two groups with the Student t-test for
independant samples for quantitative variables. Between pre- and posttreatment within the two
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groups the Student t-test for matched samples was used. Qualitative variables, improvement or not,
were tested with Fisher’s exact test. Testing was performed one-sided because greater improvement
was expected with PPS than with placebo; p<0.05 was considered to be statistically significant.
RESULTS
A total of 20 consecutively diagnosed IC patients were enrolled in the study from May ’94 to
December ’94. All the patients not only met but exceeded the NIH criteria. Despite severe symp-
toms, only one patient refused to participate in the placebo-controlled study. One patient did not
complete 3 months of treatment and was excluded from further analysis. Nine patients received PPS
and 10 received placebo. All the patients were women, with an average age of 53.8 years (range 24
- 75 years) in the PPS group versus 52.8 years (range 24 - 79) years in the placebo group. The
average duration of the disease was 5.4 years (range 1-18 years) in the PPS group and 4.1 years
(range 2-9 years) in the placebo group. Mean bladder capacity under anesthesia (1 minute at 80
cm/H2O) was 305 ml in the PPS group, versus a mean of 243 ml in the placebo group. The bladder
biopsies of all the patients showed features associated with interstitial cystitis syndrome, such as
transitional-cell erosion, monuclear infiltrates and mast cells. A moderate to high density of mast
cells was observed in seven patients from the PPS group, and in eight from the placebo group.
Subjective and objective parameters in the two groups were comparable at the start of the study.
Patients retained the pentosanpolysulfate intravesically for as long as urge and pain made it
possible. Retention varied from 30 to almost 180 minutes, without irritative side-effects. Nineteen
of the patients managed with self-catheterisation, while one was assisted by a district nurse. Urine
cultures remained negative. The main expected side-effect, hematuria, attributed to the heparin-like
qualities of the drug, was reported incidentally after instillation. The hematuria always disappeared
spontaneously within 2 days, never necessitating a medical consult.
After three months of treatment, an overall subjective improvement in symptoms was reported
by four patients (44%) in the PPS group (n=9), by two (20%) in the placebo group (n=10). This
difference was not statistically significant. All other patients reported unchanged symptoms. Table 1
shows the mean values of the objective parameters. Except for the urodynamic capacity other,
marginal, differences were not statistically significant. A decrease was noted in the average voiding
volume in the PPS-after-placebo group caused by a dramatic decrease in one patient who remained
symptomatically unchanged. A statistically significant increase (p=0.047, Student t-test, one-tail
probe) in the urodynamic capacity was recorded after 3 months of PPS treatment compared to the
58
pre-trial volume. The increase (from 208 to 229 ml) in the patients receiving PPS after placebo was
not statistically significant.
Following the placebo-controlled period of three months eleven (55%) patients continued PPS
instillations. Four patients did not continue because they judged their symptoms acceptable while
five patients preferred other conservative options. From the group of patients (n=8) who continued
with PPS after 3-months-placebo six (75%) reported symptomatic improvement and mean objective
parameters improved although, not statistically significant (Table 1).
Table 1.






Start 3m Start 3m 6m*
Frequency/24-hrs 18x 18x 22x 24x 19x
Nocturia/24-hrs 4.0x 2.8x 5.0x 5.0x 4.3x
Average volume/24-hrs 116 ml 125 ml 91 ml 107 ml 70 ml
Urodynamic capacity 226 ml 265 ml** 202 ml 208 ml 229 ml
First desire volume 73 ml 74 ml 101 ml 102 ml 67 ml
* = Patients receiving intravesical PPS during 3 months following initial treat-
ment with placebo instillations (n=8).
** = statistically significant increase, p = 0,047
From the 3 patients who continued, following 3-months PPS instillations, 2 reported further impro-
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vement and one sustained relief of symptoms. Comparison of short-term and long-term results of
PPS instillations was prohibited due to a change in frequency ( 3 times per week) and composition
of the instillations in most of the patients. At one and a half year from the start of the study 8
(40%) of the patients were still receiving PPS instillations; surgical treatment had been applied to 4
(20%) patients, twice after failure of continued PPS instillations and twice after exhausting other
conservative options (prolonged hydrodistension under anesthesia, corticosteroids).
DISCUSSION
The primary subjective measurement used to determine effectiveness was the patient evaluation of
overall improvement. In the group of patients treated with PPS, 44% experienced symptomatic
relief versus 20% of the patients treated with placebo. This difference was not statistically signifi-
cant. Differences between objective parameters were marginal, only functional bladder capacity
showed a statistically significant increase in patients treated with PPS. Eleven (55%) patients
continued PPS instillations after completion of the study protocol. One and a half year from the
start of the study eight (40%) patients are still on treatment.
The treatment of IC is largely empiric because of the unknown cause of the disease. A wide
variety of oral and intravesical agents are currently employed11. Employment of pentosanpolysulfate
in the treatment of IC is based on the pathogenetic theories referred to previously. The pharma-
cological effect of PPS is affinity for mucosal membranes, which results in coating of the surface,
particularly where the normal sulfonated glycosaminoglycan layer is missing. Furthermore, PPS
inhibits inflammatory processes involving lysosomal proteases and inflammatory mediators. Becau-
se pentosanpolysulfate orally is absorbed only marginally (3-5%) from the gastro-intestinal tract, we
hoped to improve its therapeutic efficacy by intravesical application. The dose we applied was
similar to the daily oral prescription (300 mg) and arbitrarily instilled twice a week for a period of
3 months. The double-blind design of the study offered the option of cross-over. However, it was
considered inhumane to ask patients with persistent symptoms and pain to risk another three
months of only placebo treatment. Reports on oral pentosanpolysulfate have shown moderate to
substantial relief of symptoms in 50% up to 80%4,6. However, these were un-controlled studies. The
main results and characteristics of four placebo-controlled oral PPS studies and our intravesical
placebo-controlled PPS trial are shown in Table 25,7,8,10.
Table 2.
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Placebo-contolled studies on pentosanpolysulfate for IC.





Parsons et al.; USA6 oral 1987 n=75 17% - 40% 18% S
Holm-Bentzen et al.;
Europe7
oral 1987 n=43 9% 63 yrs 30% 20% NS
Mulholland et al.;
USA8
oral 1990 n=110 11% 44 yrs 28% 13% S
Parsons et al.; USA9 oral 1993 n=148 12% 43 yrs 32% 16% S
Bade et al.; Europe intravesical 1995 n=20 5% 53 yrs 44% 20% NS
S = Statistically significant difference (p<0.05)
NS = Not statistically significant difference
The oral studies are well compatible in respect of the number of included patients, drop-out
percentage and methodology. All of them employed visual analogue scales to evaluate improve-
ment, either subdivided in points (0-5)7 or in percentages (0-25%-50%-75%-100% improvement)9
and all studies included patients who failed to respond to prior conservative treatment. However,
compared to the placebo-controlled studies from the USA, the European studies lack statistically
significance. Our recent epidemiologic study in The Netherlands revealed that general and specific
(mast cells) pathological features of bladder biopsies are the mainstays of diagnosis for Dutch
urologists12. The study of Holm-Bentzen et al. included, in the IC group, only patients with patholo-
gically anatomically verified IC (28 or more mast cells per mm2). In contrast, the USA studies used
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the clinical and endoscopic based NIH criteria to diagnose interstitial cystitis. In addition, one may
speculate about a difference in awareness concerning the diagnosis of interstitial cystitis. This
suspected transatlantic difference in definition and awareness of IC might well explain for the
higher average age and the smaller number of included patients in European studies. Compared to
the study of Holm-Bentzen et al. our study demonstrated a similar placebo effect; however, the
efficacy of intravesical PPS was higher than with oral PPS.
Three additional observations were made on the use of intravesical PPS. One (1): All but one of
the patients were successfully instructed in self-catheterisation by experienced nurses at the Urology
Diagnostic Centre. Self-catheterisation enabled patients to contribute and participate in their own
treatment which certainly influenced the psychological impact of the treatment. This is reflected in
the low drop-out percentage (5%) compared to oral PPS studies. Two (2): No side-effects were
recorded. The duration of medication retention was always determined by the slow exacerbation of
symptoms, never by side-effects. This is an advantage of PPS instillations compared to DMSO
applications. The garlic halitus of DMSO is well known and irritative symptoms or complications
do occur. A controlled study of DMSO in IC (n=30) reported 5 patients with complications from
the instillation and in two of them treatment was discontinued13. The third (3) and probably most
encouraging observation refers to the eleven (55%) patients who decided to continue PPS treatment
after termination of the first 3-months-period of the study. At one and a half year from the start of
the study eight (40%) patients were still using intravesical PPS. However, in four (20%) patients
urinary diversion had been inevitable. This percentage is relatively high and might reflect the
severity of symptoms and high number of ’end-stage IC’ in the included IC patients. Even more
appreciable is the percentage (40%) of patients still benifiting of intravesical PPS one and a half
year from the start of the study. In a study on intravesical heparin (n=48) Parsons et al. reported a
long-term remisson with continued treatment in 31% of the patients14. However, this was an
uncontrolled study. The importance of placebo-controlled studies has well been demonstrated in the
studies on oral PPS, and was confirmed by our observation of symptomatic improvement (75%) in
the patients who received intravesical PPS after termination of the placebo- and blinded period of
the study. Placebo-controlled studies are essential to determine the value of new treatment modali-
ties.
CONCLUSIONS
We concluded the efficacy of intravesical PPS to be slight superior to oral PPS. In addition, self-
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catheterisation enabled long-term treatment and fascilitated the ’self-help’ capacity of IC patients.
Whether a longer, more intense course of intravesical PPS or a combination with other agents will
produce better results is currently under investigation.
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